Meyka Pro is live. Get 50% off your first 3 months.Get Started →
Meyka Pro banner
Spyre Therapeutics, Inc.

Spyre Therapeutics, Inc. (SYRE) Stock Overview

Explore Spyre Therapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.

SYRE●NASDAQ
HealthcareBiotechnology
$106.45
$2.47(2.26%)
U.S. Market is Open · 15:43

Spyre Therapeutics, Inc. (SYRE)

Meyka AI Score

Z

Key Financials

Market Cap9.4B
P/E Ratio-54.95
EPS (TTM)$-1.95
ROE-0.24%
Fundamental Analysis

AI Price Forecasts

1 Month$100.02
3 Months$72.63
1 Year Target$20.72

SYRE Stock Analysis & Investment Overview (NASDAQ)

Our AI-powered analysis of Spyre Therapeutics, Inc. (NASDAQ: SYRE) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, Spyre Therapeutics, Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of SYRE on the NASDAQ shows an RSI of 58.85, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $20.72 for the NASDAQ listing.

Key metrics behind Spyre Therapeutics, Inc.'s NASDAQ-traded stock include a P/E ratio of -54.95 and a market capitalization of 9.4B. Combined with our AI analysis, these give both institutional and retail investors a clear view of SYRE on the NASDAQ.

Price Performance (NASDAQ: SYRE)

1-Day Change
-1.04%
5-Day Change
6.50%
1-Month Change
10.75%
3-Month Change
49.87%
6-Month Change
149.46%
Year-to-Date (YTD) Change
229.03%
1-Year Change
559.27%
3-Year Change
762.32%
5-Year Change
-38.49%
All-Time (Max) Change
-55.87%

Contact Information

https://www.spyre.com
617 651 5940
Building 23, Waltham, MA, 02453

Company Facts

1,250 Employees
IPO DateApr 7, 2016
CountryUS
Actively Trading

Frequently Asked Questions